Document:

axsm_Ex10_1

		
			Exhibit 10.1
		

			
					
						 

					
					
						 

				
	
					
						

					
					
						Axsome Therapeutics, Inc.
25 Broadway
9th Floor
New York, NY 10004
Tel: +1 212.332.3241
Fax: +1 212.320.0245
www.axsome.com

				

		
			July 5, 2017
		

		
			John Golubieski
22 Tulsa Court
Monmouth Junction, NJ 08852
		

		
			Dear John:
		

		
			I am pleased to offer you the opportunity to join us at Axsome Therapeutics, Inc. (the “Company”). I truly believe that you will be a great addition to our team. We are pleased to offer you employment in the position of Chief Financial Officer on the following terms:
		

			
	
			
				 ·
			

			
	
			
			Your annual base salary will be $325,000 with an anticipated start date of August 4, 2017. Your base salary, less payroll deductions and required withholdings, will be payable in accordance with the Company’s normal payroll practices. You may also receive a discretionary cash bonus up to 40% of your base salary, prorated based on your start date and contingent upon your performance and availability of funds. You will receive a sign-on bonus of $50,000 which you will be required to repay in full if you voluntarily leave the Company within one year of your start date. 

			
	
			
				 ·
			

			
	
			
			Subject to approval by the Board of Directors of the Company (the “Board”), you will receive options to purchase 132,000 shares of common stock (the “Shares”) under the Company’s Equity Compensation Plan (the “Plan”). The options, if approved, will vest over a four-year period as follows: 25% of the Shares on the first anniversary of the date of grant, and the remaining 75% of the Shares in equal increments thereafter each quarter of the remaining three years. The options will have an exercise price equal to the closing price of the common stock on the date of grant. The options are governed by and subject to the Plan and any grant agreements, which you will receive under separate cover.

			
	
			
				 ·
			

			
	
			
			Naturally, your compensation, including base salary, bonus and options, is contingent upon your continued employment with the Company. Your title and compensation will be reviewed periodically (not less often than annually) by the Chief Executive Officer and the Board.

			
	
			
				 ·
			

			
	
			
			You will be eligible to participate in all employee benefit plans or programs of the Company offered generally to similarly situated employees of the Company, subject to the terms and provisions of such plans including applicable waiting periods. Details about these benefits will be made available for your review. The Company retains the right to modify, replace or terminate any or all of its employee benefits plans or programs from time to time.

			
	
			
				 ·
			

			
	
			
			You may terminate your employment with the Company at any time and for any reason whatsoever. Likewise, the Company may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This at-will employment relationship cannot be changed except in writing signed by the Chief Executive Officer.

			
	
			
				 ·
			

			
	
			
			Notwithstanding your at-will employment, in the event the Company terminates your employment without Cause within 12 months of a Change in Control of the Company, you will be eligible to receive severance payments equal to six (6) months of your then existing base salary, with payment beginning 

		 

 

	within 10 days after the Release (as defined below) becomes irrevocable, effective and enforceable. Payments shall be made in equal monthly installments over a period of 6 months from the date on which the Release becomes irrevocable, effective and enforceable,  with each such payment due by the 15th of each month thereafter with the exception of the first payment, which shall be due within 10 days after the Release become irrevocable, effective and enforceable.. The Company’s obligation to make any payment or provide any benefit pursuant to this paragraph is contingent upon, and is the consideration for, you executing a comprehensive separation and general release agreement that includes provisions relating to cooperation, non-admissions, non-disclosure, non-disparagement, return of all property and other terms in a form acceptable to the Company (“the Release”) and that becomes effective in accordance with its terms on or before the 60th day after the date of termination. You also must comply and continue to comply with your obligations under the Release and the attached Employee Proprietary Information and Inventions Agreement,  and you must reasonably cooperate and be responsive and available upon reasonable requests by the Company to assist the Company pertaining to areas of the Company’s business of which you have knowledge as a result of your employment hereunder. For the purposes of this paragraph, “Cause” means (i) your repeated intentional failure to perform, or repeated gross negligence in the performance of, one or more of your essential duties and responsibilities to the Company and/or your failure to follow the lawful directives of the Company;  (ii) your extended or repeated absence from the Company’s offices or unavailability to perform services hereunder other than as a result of Company-related travel or paid time off;  (iii) your conviction of a felony or your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company;  (iv) your unauthorized use or disclosure of any material proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; (v) any material breach by you of this Agreement or any related agreements with the Company including, but not limited to, any non-competition or non-solicitation provision; (vi) your deliberate and material violation of any Company policy; (vii) your death or any disability that renders you, in the good faith determination of the Company, unable to perform the essential duties and responsibilities of your job with or without a reasonable accommodation. “Change in Control” means the sale of all or substantially all the assets of the Company; any merger, consolidation or acquisition of the Company with, by or into another corporation, entity or person; or any change in the ownership of more than fifty percent (50%) of the voting capital stock of the Company in one or more related transactions.

			
	
			
				 ·
			

			
	
			
			Without the express written consent of the Chief Executive Officer, you shall have no apparent or implied authority to pledge the credit of the Company, to bind the Company under any contract, note, mortgage or other agreement outside the ordinary course of the Company’s business, to release or discharge any debt due to the Company, or to sell, mortgage, transfer or otherwise dispose of any assets of the Company.

			
	
			
				 ·
			

			
	
			
			You will abide by the Company’s rules and regulations, now existing or established hereafter, including without limitation the Company’s Insider Trading Policy and Code of Conduct and Ethics. As a condition of employment, you must sign and comply with the Employee Proprietary Information and Inventions Agreement attached hereto as Exhibit A, which includes a prohibition on the unauthorized use or disclosure of the Company’s confidential or proprietary information, a prohibition against engaging in competitive activities or soliciting employees of the Company during, and for one year after the end of, your employment with the Company, and provisions acknowledging the Company’s ownership in, and assigning to the Company all rights to, any inventions developed by you during your employment with the Company.

			
	
			
				 ·
			

			
	
			
			You represent to the Company that your performance will not breach any other agreement to which you are a party and that you have not, and will not during the term of your employment with the Company, enter into any oral or written agreement in conflict with any of the provisions of this letter agreement or the Company’s policies. You will not use or disclose to any person associated with the 

		 

 

	Company, any confidential or proprietary information belonging to any former employer or other third party with respect to which you owe an obligation of confidentiality under any agreement or otherwise. The Company does not need and will not use such information and we will assist you in any way possible to preserve and protect the confidentiality of proprietary information belonging to third parties.

			
	
			
				 ·
			

			
	
			
			In the event of a breach by you of any of your obligations of this letter agreement, including Exhibit A,  you shall cease to be entitled to any further benefits under this letter agreement. You agree that all bonuses, equity compensation and other incentive compensation provided by the Company shall be subject to any applicable clawback policy implemented by the Board of Directors from time to time.

			
	
			
				 ·
			

			
	
			
			This letter agreement is binding upon and inures to the benefit of both parties and the Company’s assigns and successors, including without limitation any entity with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business,  provided, however, that any assignee, or successor in interest, assumes the Company’s obligations hereunder. Your rights and obligations under this letter agreement are personal and cannot be transferred or assigned by you at any time.

			
	
			
				 ·
			

			
	
			
			This letter agreement, together with (i) any equity award agreements, and (ii) all agreements attached hereto or referenced herein, constitute the entire agreement and understanding of the Company and you with respect to the terms and conditions of your employment with the Company and the eligibility for any potential severance payments following separation from employment with the Company, and this letter agreement shall supersede all prior and contemporaneous written or oral agreements, promises and understandings between you and the Company relating to such subject matter. This letter agreement may only be amended by written instrument signed by you and the Chief Executive Officer. This letter agreement shall be construed and interpreted under the laws of the State of New York without regard to the conflicts of laws provisions thereof.

			
	
			
				 ·
			

			
	
			
			You will be required to complete and return a W-9 federal tax withholding form so that we can process your first pay period. In preparing your W-9, remember to write your name exactly as it appears on your social security card or work visa. To the extent required by law, this offer is subject to satisfactory proof of your right to work in the United States. This offer is contingent upon the successful completion of reference and background checks.

			
	
			
				 ·
			

			
	
			
			By signing below, you represent that you are not relying on any representation, promise or agreement that is not expressly written in this letter agreement or in Exhibit A.

		
			Once again, I am thrilled you are joining us. I believe you are really going to enjoy working here, and I know you will add tremendous value. Feel free to call me with any questions.
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Sincerely,

				
	
					
						 

					
					
						 

					
					
						 

					
						/s/ Herriot Tabuteau, MD

					
						 

				
	
					
						 

					
					
						 

					
					
						Herriot Tabuteau, MD

				
	
					
						 

					
					
						 

					
					
						Chief Executive Officer

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						AGREED TO AND ACCEPTED:

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ JOHN GOLUBIESKI

					
					
						 

					
					
						 

				
	
					
						 

					
						John Golubieski

					
					
						 

					
					
						 

				
	
					
						Date: July 5, 2017

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

 

		

		
			EXHIBIT A
		

		
			EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENTExhibit 10.1

 

AMENDMENT TO EXTEND CONTRACT FOR THE PROVISION OF PHYSICAL &

BEHAVIORAL HEALTH SERVICES UNDER THE GOVERNMENT HEALTH PLAN

PROGRAM

 

WHEREAS, Administración de Seguros de Salud de Puerto Rico (“ASES”) and Triple-S Salud, Inc. (the “Contractor” and together with ASES, the “Parties”) have executed a Contract for the Provision of Physical Health and Behavioral Health Services Under the Government Health Plan within the Commonwealth of Puerto Rico for the Metro North and West Service Regions, (hereinafter referred to as the “Agreement”), pursuant to which ASES pays the Contractor a fixed monthly per capita amount for the rendering of services to beneficiaries of the Government Health Plan during the Commonwealth of Puerto Rico’s 2016-2017 fiscal year (the "Current PMPM Payments");

 

WHEREAS, pursuant to Article 21.6 of the Agreement, ASES exercised its option to renew the Agreement for a period of one year, beginning July 1, 2017 and ending June 30, 2018 (the "Renewal");

 

WHEREAS, Article 21.6 provides that “the terms of the renewal shall be negotiated, but any increase in PMPM Payment shall be subject to ASES’s determination that the proposed new amount is actuarially sound”;

 

WHEREAS, the Parties agreed on new PMPM Payments of $183.38 in the Metro North Service Region and $148.99 in the West Service Region (the “New PMPM Payments”) for the term of the Renewal, and ASES determined that such payments are actuarially sound;

 

WHEREAS, the Parties continue negotiating other terms of the Renewal and must obtain approval from the Centers for Medicare & Medicaid Services (“CMS”) of ASES’ actuarial certification of the New PMPM Payments before ASES can apply such payments to services rendered under the Renewal;

 

WHEREAS, the Parties have agreed to amend the Agreement to extend its term for a period of three (3) months and provide a mechanism to adjust payments to the Contractor to account for the difference between the Current PMPM Payment and the New PMPM Payment once CMS approves ASES’ actuarial certification; and

 

WHEREAS, all remaining provisions of the Agreement will remain in full force and effect during the Extension Period.

 

NOW THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, the adequacy and receipt of which are hereby acknowledged, the Parties have agreed to amend the Agreement as follows:

 

AGREED EXTENSION

 

FIRST: THE PARTIES HEREBY EXTEND the Agreement for one (1) additional term of three (3) months, to expire on September 30, 2017 (the "Extension Period");

 

SECOND: All provisions of the Agreement will remain in full force and effect during the Extension Period, including the terms of the physical and behavioral health services provided under the Agreement, with the exception of the Per Member Per Month (“PMPM”) Payments set forth in Section 22.1.1.1 of the Agreement, which are hereby amended to reflect the New PMPM Payments, provided that such rates will be subject to CMS approval of ASES’ actuarial certification (the “CMS Approval”);

 

THIRD: The Parties hereby acknowledge and accept that within 30 days of the CMS Approval, ASES will pay the cumulative difference between the New PMPM Payments and the Current PMPM Payments effectuated between July 1, 2017 and the date of CMS Approval, and will prospectively pay the New PMPM Payments until the expiration or earlier termination of the Extension Period;

FOURTH: The Parties further agree that in the event CMS does not approve the New PMPM Payments, the Parties will commit to engage their respective actuaries in a joint exercise to address any CMS objections until the CMS Approval is obtained, and upon such approval, the parties agree that the rates approved by CMS shall become the New PMPM Payments of the Extension Period and the Renewal for all intents and purposes.  Furthermore, if the Parties are unable to agree by July 31, 2017 on other terms of the Renewal that are still subject to negotiation as of the signing of this Extension Agreement, ASES shall grant the Contractor the right to not enter into the Renewal.

ACKNOWLEDGED BY THE PARTIES by their duly authorized representatives on this 30th day of June, 2017.

 

	
 

	
Administración de Seguros de Salud de Puerto Rico (ASES)

	
 

	
 

	
 

	
/s/ Angela M. Ávila Marrero

	
 

	
Ms. Angela M. Ávila Marrero, Executive Director

	
 

	
 

	
 

	
Triple-S Salud, Inc.

	
 

	
 

	
 

	
/s/ Madeline Hernández Urquiza

	
 

	
Madeline Hernández Urquiza, President

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]